Order Information
Contact us
Insert title here
Featured Products
HY-10005  |  Flavopiridol
HY-10008  |  SNS-032
HY-10012  |  AZD-5438
HY-10014  |  R547
HY-10032  |  PF 477736
HY-10087  |  Navitoclax
HY-10128  |  ZM-447439
HY-10161  |  Tozasertib
HY-10180  |  MLN8054
HY-10192  |  NVP-TAE 684
HY-10228  |  Motesanib
HY-10249  |  GSK-690693
HY-10355  |  AKT inhibitor VIII
HY-10358  |  MK 2206 (dihydrochloride)
HY-10992  |  AZD-7762
HY-10997  |  PCI-32765
HY-11001  |  PHA-793887
HY-11002  |  CP-466722
HY-11007  |  GNF-2
HY-11009  |  CGP60474


 (Synonyms  AMG 706;)
453562-69-1  Technical Data: Price and Availability of  Cas No:453562-69-1

Cas : 453562-69-1 M.Wt: 373.4509
Cas : 453562-69-1 Formula: C22H23N5O
Cas : 453562-69-1 Purity: >98 %
Cas : 453562-69-1 Storage: at 20℃ 2 years
Cas : 453562-69-1 Solubility: DMSO: ≥ 30 mg/mL
Cas : 453562-69-1 Name: Motesanib
10mg/$50 In-stock
50mg/$160 In-stock
100mg/$280 In-stock
200mg/$360 In-stock
500mg/$810 In-stock
1g Get quote
5g Get quote
>10g Get quote
We match the lowest price on market.
We offer a substantial discount on larger orders,please
inquire via sales@chemexpress.cn
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
Online Inquiry
453562-69-1  Data Sheet:
Introduction of 453562-69-1 :
Motesanib is a potent ATP-competitive inhibitor of?VEGFR1/2/3?with?IC50s?of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.? IC50 & Target: IC50: 2 nM (VEGFR1), 3 nM (VEGFR2), 6 nM (VEGFR3) In Vitro: Motesanib has broad activity against the human VEGFR family, and displays > 1000 selectivity against EGFR, Src, and p38 kinase. Motesanib significantly inhibits VEGF-induced cellular proliferation of HUVECs with an IC50 of 10 nM, while displaying little effect at bFGF-induced proliferation with an IC50 of >3,000 nM. Motesanib also potently inhibits PDGF-induced proliferation and SCF-induced c-kit phosphorylation with IC50 of 207 nM and 37 nM, respectively, but not effective against the EGF-induced EGFR phosphorylation and cell viability of A431 cells[1].?Althouth displaying little antiproliferative activity on cell growth of HUVECs alone, Motesanib treatment significantly sensitizes the cells to fractionated radiation[2].? In Vivo: Motesanib (100 mg/kg) significantly inhibits VEGF-induced vascular permeability in a time-dependent manner. Oral administration of Motesanib twice daily or once daily potently inhibits, in a dose-dependent manner, VEGF-induced angiogenesis using the rat corneal model with ED50 of 2.1 mg/kg and 4.9 mg/kg, respectively. Motesanib induces a dose-dependent tumor regression of established A431 xenografts by selectively targeting neovascularization in tumor cells[1]. Motesanib in combination with radiation displays significant anti-tumor activity in head and neck squamous cell carcinoma (HNSCC) xenograft models[2].?Motesanib treatment also induces significant dose-dependent reductions in tumor growth and blood vessel density of MCF-7, MDA-MB-231, or Cal-51 xenografts, which can be markedly enhanced when combined with docetaxel or tamoxifen[3].?
References on 453562-69-1 :

Keywords: buy Motesanib | Motesanib Supplier | purchase Motesanib | Motesanib cost | Motesanib manufacturer | order Motesanib | Motesanib distributor | Motesanib structure
buy 453562-69-1 | 453562-69-1 Supplier | purchase 453562-69-1 | 453562-69-1 cost | 453562-69-1 manufacturer | order 453562-69-1 | 453562-69-1 distributor | 453562-69-1 structure
Insert title here
Products are for research use only. Not for human use. We do not sell to patients.           Copyright © 2009 Haoyuan Chemexpress All Rights Reserved
ADDRESS: 6/F, No. 2 Building, No. 720,Cailun Road, Shanghai, P.R.China  
86-21-58998590   FAX: 86-21-53700326, 86-21-58998590   E-mail: sales@chemexpress.cn